TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41083

Peptide_Name

Temporin-PKE-2K

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FLPLIIGKLSSLLPKIF-NH2

FASTA

>TPDB41083|Anticancer|length=17
FLPLIIGKLSSLLPKIF-NH2

Formula C96H159N19O20

Absent Amino Acids ARNDCEQHMTWYV

Common Amino Acids L

Mass 1899.43

PI 10.60

Basic Residues 2

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +2

Boman Index -2.84

Hydrophobicity 1.476

Aliphatic Index 183.53

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

0

H

3

I

5

L

2

K

0

M

2

F

2

P

2

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 5 K: 2 M: 0 F: 2 P: 2 S: 2 T: 0 W: 0 Y: 0 V: 0

Length

17

Formula

C96H159N19O20

Mass

1899.43

PI

10.60

Net Charge

+2

Boman Index

-2.84

Hydrophobicity

1.476

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.49 µM

Detail Source Activity Anticancer

Activity Measurement 2.49 µM

Target

Cancer Type Brain Tumor

Cell Line U251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.64 µM

Detail Source Activity Anticancer

Activity Measurement 2.64 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 3.07 µM

Detail Source Activity Anticancer

Activity Measurement 3.07 µM

Target

Cancer Type Lung Cancer

Cell Line H-838

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.84 µM

Detail Source Activity Anticancer

Activity Measurement 2.84 µM

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.78 µM

Detail Source Activity Anticancer

Activity Measurement 2.78 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022